Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Blood|June 26, 2020
Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphomaHyera Kim, Hyehyun Jeong, Motoko Yamaguchi, et al.
Blood Advances|November 20, 2020
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville scoreHo-Young Yhim, Yael Eshet, Ur Metser, et al.
Scientific Reports|January 1, 2020
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysisJung Yong Hong, Dok Hyun Yoon, Sang Eun Yoon, et al.
Blood|June 12, 2026
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01)Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, et al.
Cancer Research and Treatment|July 16, 2024
Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC StudyYoon Seok Choi, Joonho Shim, Ka-Won Kang, et al.
Cancer Research and Treatment|November 6, 2025
Impact of Cell-of-Origin and MYC/BCL2 Status on the Risk of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell LymphomaChang-Hoon Lee, Ga-Young Song, Ho-Young Yhim, et al.
Frontiers in Immunology|March 20, 2023
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infectionsJinyoung Yang, Gunho Won, Jin Yang Baek, et al.
Blood|March 12, 2025
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell LymphomaSeok Jin Kim, Jing Quan Lim, Sang Eun Yoon, et al.
Cancers|February 13, 2026
Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 StudyJongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, et al.
Blood Cancer Journal|December 2, 2021
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CTHee Jeong Cho, Sung-Hoon Jung, Jae-Cheol Jo, et al.
Pageof 14